Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
About this study
For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and stage III colorectal cancer after radical resection.
- Condition
- Stage II Colorectal Cancer, Stage III Colorectal Cancer
- Tested
- Thymosin Alpha1
- Sponsor
- Fudan University
Who can join
- Age
- 18 to 75 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 75 years
- Study condition: Stage II Colorectal Cancer, Stage III Colorectal Cancer
- Colorectal cancer receiving radical resection
- Pathologically diagnosed with high-risk stage II or stage III
- Eastern Cooperative Oncology Group performance status of 0-2
- Adequate hepatic, renal, and hematologic function
Exclusion 2
- Had previously taken any immune-promoting drugs
- Pregnancy or lactation
Where
1 site, 1 recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact
-
Jianmin Xu, Dr.
+86-021-64041990 xujmin@aliyun.com
-
Qingyang Feng, Dr.
+86-021-64041990 fqy198921@163.com
Potential match only. Final eligibility is determined by the study team.